Dublin-based generic and specialty drug company Actavis plc (NYSE:ACT) is a pharma deal-maker. Much of Actavis’ growth as a company has been …
As widely expected, the new year has begun with a lot of volatility on high trading volume, as investors fear more than just …
Another solid year for U.S.
This has not been an easy year for hedge funds. The most popular hedge fund strategy, long/short equity, which usually churns out an …
S&P Capital IQ, a leading provider of multi-asset class research data and insights, has announced the release of its review of 2014 Q3 …
I wrote about generic and specialty drug company Actavis plc (NYSE:ACT) a while back detailing the rumored love triangle between them, Allergan (NYSE:AGN), …
Back on July 3rd of this year, I wrote about a good find in pharma called Salix Pharmaceuticals (NASDAQ:SLXP). Salix Pharmaceuticals is a …
In a research note released yesterday, Cannacord Genuity analyst Corey Davis reaffirmed a Buy rating on Actavis (ACT) with a price target of …
In a research report issued Thursday, Canaccord analyst Corey Davis initiated coverage with a “Buy” rating on Actavis plc (ACT) and a price target of $275.00 a share, representing a potential …